See the DrugPatentWatch profile for Fetzima
The generic name for Fetzima is levomilnacipran [1].
What is levomilnacipran used for?
Levomilnacipran is a serotonin and norepinephrine reuptake inhibitor (SNRI) used to treat major depressive disorder (MDD) in adults [2]. It works by increasing the levels of serotonin and norepinephrine in the brain, which can help improve mood and reduce symptoms of depression [3].
When will the patent for Fetzima expire?
The patent for Fetzima is expected to expire in 2027 [4]. This expiration date is a key factor in determining when generic versions of the drug may become available. Information regarding specific patent details and their expiry can be found on DrugPatentWatch.com [4].
What is the difference between Fetzima and other antidepressants?
Levomilnacipran's mechanism of action as an SNRI distinguishes it from other classes of antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) which primarily affect serotonin levels, or tricyclic antidepressants (TCAs). Its specific balance of serotonin and norepinephrine inhibition may offer a different therapeutic profile for some patients [3].
Can generic levomilnacipran be manufactured before patent expiry?
Generally, generic drug manufacturers must wait until the relevant patents and market exclusivity periods expire before they can legally produce and market a generic version of a branded drug. This is to protect the innovator company's investment in drug development [4].
What are the potential risks or side effects of levomilnacipran?
Common side effects of levomilnacipran may include nausea, constipation, increased heart rate, increased blood pressure, insomnia, and sweating [2]. As with all medications, there are also potential serious side effects, and patients should discuss these with their healthcare provider [3].